Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 29 March 2011
[DOI: 10.1126/scisignal.2001752]

Supplementary Materials for:

Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

Annette S. Little,* Kathryn Balmanno, Matthew J. Sale, Scott Newman, Jonathan R. Dry, Mark Hampson, Paul A. W. Edwards, Paul D. Smith, Simon J. Cook*

*To whom correspondence should be addressed. E-mail: annette.little{at}bbsrc.ac.uk (A.S.L.); simon.cook{at}bbsrc.ac.uk (S.J.C.).

This PDF file includes:

  • Fig. S1. Growth curves of HCT116 and H6244-R1 or COLO205 and C6244-R1 cells and growth factor–independent proliferation.
  • Fig. S2. AZD6244-resistant cells are cross-resistant to other MEK inhibitors.
  • Fig. S3. AZD6244-resistant cells are not cross-resistant to cytotoxic drugs.
  • Fig. S4. Kinetics of emergence of AZD6244 resistance.
  • Fig. S5. Genomic PCR demonstrates amplification of BRAF and KRAS but not cyclin D1 in C6244-R1 and H6244-R1 cells.
  • Fig. S6. BRAF and KRAS mutation analysis.
  • Fig. S7. H6244-R1 cells show increased PI3K-PKB pathway signaling, but C6244-R1 cells do not.
  • Fig. S8. Heat map of differential expression of a gene expression signature indicative of RAS activation in HCT116 versus H6244-R1 cells and COLO205 versus C6244-R1 cells.
  • Fig. S9. Resistance to AZD6244 in C6244-R1 cells is reverted upon prolonged withdrawal of the drug.
  • Fig. S10. Different methods of generating AZD6244-resistant cells give rise to a common mechanism of resistance.
  • Fig. S11. HCT116 cells rendered resistant to PD184352 (H184-R) also show increased abundance of KRAS.
  • Table S1. Summary of primers and probes used for the BRAF and KRAS qPCR assays.
  • Table S2. Summary of primers used in the mutation screen to amplify the required regions for sequencing.
  • Table S3. Summary of genetic background of cell lines used.
  • Table S4. Weighting values relative to the performance of genes for the "MEK functional activation" and "Compensatory resistance" gene signatures specifically within colorectal cancer (CRC) samples.

[Download PDF]

Technical Details

Format: Adobe Acrobat PDF

Size: 1.57 MB

 


Citation: A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook, Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells. Sci. Signal. 4, ra17 (2011).

© 2011 American Association for the Advancement of Science


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882